An observational study in RSV Infection, Quality of Life and Infant ALL, sponsored by Global Foundation for the Care of Newborn Infants. Status unknown at 1 site in Germany. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by Global Foundation for the Care of Newborn Infants · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Respiratory Syncytial Virus Infections with a site in Germany — none open to participants now, 3 under way, 2 of them phase 3. Respiratory Syncytial Virus Infections · Germany.
Among the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 20th registered.
307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 50 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 12
First in 2004; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 120 is below the median of 375 across 76 observational studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 964 across the 22 interventional studies, 350 across the 3 observational. Of the 20 that completed or were terminated, 17 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
Global Foundation for the Care of Newborn Infants is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Global Foundation for the Care of Newborn Infants has 1 study filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Respiratory Syncytial Virus Infections with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Until today, there is only little information available on how severe RSV infection leading to hospitalisation of the infant impacts the quality of life of affected families. For the ResQ Family project, an online questionnaire will be used to survey parents or caregivers of children up to 24 months currently or recently hospitalised (length of hospital stay of at least 12 hours and hospital admission no longer than 4 weeks ago) due to RSV infection.
The aim of the ResQ Family project is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public. The project will run until June 2024. Data collection will take place during the RSV season from fall 2022 to spring 2023 in four European countries: France, Germany, Italy, and Sweden.
Respiratory Syncytial Virus (RSV) is a very contagious virus and the most common cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants. By the age of two years, nearly all infants will be infected with RSV at least once. Globally, it is a leading cause of hospitalisations among young infants with approximately 33 million cases of acute lower respiratory infections causing more than three million hospitalisations each year in children younger than 5 years. While most RSV cases are mild, one can't predict which infants could get seriously ill and end up in hospital. This is because the course of the disease is unpredictable.
When the RSV infection of the child is severe and associated with hospitalisation, it may lead to intensive care unit admissions with use of supportive care such as mechanical ventilation. It may further result in long-term complications such as recurrent wheezing, reduced pulmonary function and asthma. Moreover, RSV-related hospitalisations can be associated with a significant burden on the entire family, causing considerable stress and increased loss of work productivity. Currently, there is a lack of adequate information on how severe RSV infection leading to hospitalisation of infants (\< 2 years) impacts the quality of life of affected families.
To close this knowledge gap, the ResQ Family research project was initiated: ResQ Family: Impact of Respiratory Syncytial Virus (RSV) hospitalisation on Quality of life of Families - a multi-country study. The project runs from December 2021 until June 2024 and covers four European countries: France, Germany, Italy and Sweden. Data will be collected between autumn 2022 and spring 2023, corresponding to a typical RSV season duration in temperate countries in the northern hemisphere.
The aim of the ResQ Family study is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public.
An online questionnaire will be used to ask parents and caregivers of children experiencing (or having recently experienced) hospitalisation due to RSV infection to share their experiences and a follow-up will take place after six weeks. The study focuses on children up to 24 months with a hospital stay due to RSV infection of at least 12 hours in total. The hospital admission should not be longer than 4 weeks ago.
Experienced researchers and health care professionals renowned in the field of RSV as well as parent/patient representatives support the project as part of an external scientific advisory board and a project expert group.
EFCNI received a research grant from Sanofi in support of this independent study.
Parents or caregivers of children younger than 24 months of age with a hospitalisation for at least 12 hours due to RSV infection in Germany, Sweden, Italy or France.
Inclusion Criteria:
Other: cohort study
Please note that this is an observational study; not applicable
Health-related quality of life of parents/caregivers and family functioning
The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV. It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items). Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always. Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).
Time frame: Baseline (Day 0)
Health-related quality of life of parents/caregivers and family functioning
The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV. It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items). Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always. Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).
Time frame: 6 weeks follow-up (Week 6)
Socio-demographics
Parental self-report - self-designed questions: socio-demographics (parents/caregiver), risk factors (smoking, allergic diseases), place of living, birth weight (child, categories and in grams), RSV prophylaxis, breastfeeding, day-care attendance
Time frame: Baseline (Day 0)
Child's co-morbidities
Parental self-report - self-designed questions: pre-existing health-conditions before or apart from the current recent hospitalisation due to RSV
Time frame: Baseline (Day 0)
Child's symptoms during RSV infection and hospitalisation
Parental self-report - self-designed questions: RSV diagnose (child), duration of hospitalisation (in days), supportive care measure in hospital, feelings (parents) in relation to the hospitalisation of the child (categories), presence with the child receiving special/intensive care, duration of symptoms (up to 7 days and more), child's behaviour (categories), worry of parents/caregiver about symptoms (categories)
Time frame: Baseline (Day 0)
Child's symptoms after RSV infection and hospitalisation
Parental self-report - self-designed questions: Duration of symptoms (in days), child's behaviour, worry of parents/caregiver about symptoms (categories)
Time frame: 6 weeks follow-up (Week 6)
Other
Parental self-report - self-designed questions: Health literacy, support structures, loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question)
Time frame: Baseline (Day 0)
Other
Parental self-report - self-designed questions: Loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question)
Time frame: 6 weeks follow-up (Week 6)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for May 2023, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →
Global Foundation for the Care of Newborn Infants